Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy
Authors:
- Shanwei YeSYShanwei Ye
- Liang HuangLHLiang Huang
- Li ZhuLZLi Zhu
- Wei MuWMWei Mu
Open Access
- 25 October 2024
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 27 (2) , 247-257
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 26 references indexed in Scilit:
- Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialNature Medicine, 2024
- Forks in the road for CAR T and CAR NK cell cancer therapiesNature Immunology, 2023
- CAR immune cells: design principles, resistance and the next generationNature, 2023
- T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escapeSignal Transduction and Targeted Therapy, 2022
- Harnessing natural killer cells for cancer immunotherapy: dispatching the first respondersNature Reviews Drug Discovery, 2022
- Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectorsCytotherapy, 2021
- Exploring the NK cell platform for cancer immunotherapyNature Reviews Clinical Oncology, 2020
- Evaluation of serum-free media formulations in feeder cell–stimulated expansion of natural killer cellsCytotherapy, 2020
- Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free MediaMolecular Therapy - Methods & Clinical Development, 2020
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsNew England Journal of Medicine, 2020